We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

134 hedge funds and large institutions have $315M invested in CytomX Therapeutics in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 15

24% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 38

15% more funds holding

Funds holding: 117 → 134 (+17)

5% more capital invested

Capital invested by funds: $298M → $315M (+$16.4M)

3.05% less ownership

Funds ownership: 85.28% → 82.23% (-3.1%)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $5K

Holders
134
Holders Change
+17
Holders Change %
+14.53%
% of All Funds
2.75%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
32
Increased
47
Reduced
38
Closed
15
Calls
–
Puts
$5K
Net Calls
-$5K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$12.2M
2
State Street
State Street
Massachusetts
+$11.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.59M
4
RI
RTW Investments
New York
+$4.16M
5
HIM
Hillsdale Investment Management
Ontario, Canada
+$3.47M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$30.3M
2
BI
BVF Inc
California
-$7.49M
3
MB
MPM BioImpact
Massachusetts
-$6.56M
4
PA
Perceptive Advisors
New York
-$6.29M
5
CS
Candriam SCA
Luxembourg
-$6.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
$761K +$40.9K +4,400 +5%
Axa
52
Axa
France
$737K +$822K +88,526 New
EAM
53
Exane Asset Management
France
$732K – – –
CPC
54
Congress Park Capital
New York
$719K -$114K -12,300 -12%
Arrowstreet Capital
55
Arrowstreet Capital
Massachusetts
$691K +$770K +82,952 New
3C
56
361 Capital
Colorado
$671K +$748K +80,556 New
Bessemer Group
57
Bessemer Group
New Jersey
$666K +$743K +80,000 New
HP
58
Harbourvest Partners
Massachusetts
$660K – – –
MCM
59
Moore Capital Management
New York
$625K -$232K -25,000 -25%
FQ
60
First Quadrant
California
$588K +$655K +70,559 New
State of Wisconsin Investment Board
61
State of Wisconsin Investment Board
Wisconsin
$579K – – –
GC
62
Globeflex Capital
California
$578K +$645K +69,435 New
Citadel Advisors
63
Citadel Advisors
Florida
$567K -$1.24M -134,041 -66%
California State Teachers Retirement System (CalSTRS)
64
California State Teachers Retirement System (CalSTRS)
California
$566K – – –
New York State Common Retirement Fund
65
New York State Common Retirement Fund
New York
$550K +$172K +18,483 +39%
AllianceBernstein
66
AllianceBernstein
Tennessee
$536K – – –
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$530K +$27.5K +2,956 +5%
Deutsche Bank
68
Deutsche Bank
Germany
$507K +$69.7K +7,504 +14%
SO
69
STRS Ohio
Ohio
$467K +$42.7K +4,600 +9%
Thrivent Financial for Lutherans
70
Thrivent Financial for Lutherans
Minnesota
$412K – – –
Connor, Clark & Lunn Investment Management (CC&L)
71
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$396K -$482K -51,894 -52%
AC
72
Athanor Capital
New York
$389K +$434K +46,713 New
EGM
73
Engineers Gate Manager
New York
$383K +$304K +32,786 +248%
VEA
74
Virtus ETF Advisers
New York
$367K -$57.8K -6,220 -12%
GCP
75
GSA Capital Partners
United Kingdom
$339K -$192K -20,681 -34%
1 2
3
4 5

CTMX Hedge Fund Activity: Q2 2020 in Review

134 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2020, worth a combined $315M — up 5.5% from $298M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CTMX positions and 15 closed out — a net gain of 17 holders — while 47 added to existing stakes and 38 trimmed.

The largest buyer was Great Point Partners, adding an estimated $12.2M. The largest seller was Victory Capital Management, cutting an estimated $30.3M.

  • 134 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2020, up from 117 in Q1 2020.
  • Funds reported $315M of CytomX Therapeutics stock for Q2 2020, up 5.5% quarter-over-quarter.
  • 32 funds opened new CytomX Therapeutics positions in Q2 2020 and 15 closed out, a net change of +17 holders.
  • The largest CytomX Therapeutics buyer in Q2 2020 was Great Point Partners, an estimated $12.2M added.
  • The largest CytomX Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q2 2020.